Real-world Comparative Effectiveness of Rivaroxaban Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism (RECENT)
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins; Phenprocoumon
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms RECENT
- Sponsors Bayer
Most Recent Events
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 Apr 2021 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
- 21 Apr 2021 Planned primary completion date changed from 31 Mar 2021 to 31 May 2021.